The BCR-ABL fusion protein, generated following translocation of ABL to the BCR gene, leads to constitutive activation of the ABL tyrosine kinase in 95% of chronic myeloid leukemia and cells depend on BCR-ABL activity for the execution of the oncogenic program [15]. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.